Sepsis deaths trigger FDA hold on Zentalis' azenosertib cancer studies

2024-06-18

临床1期临床2期临床结果

Zentalis Pharmaceuticals disclosed that the FDA has placed a partial clinical hold on three monotherapy studies of its lead candidate, the oral WEE1 inhibitor azenosertib WEE1 inhibitor azenosertib (ZN-c3), following two patient deaths presumed to be from sepsis. The news sent company shares sliding more than 45% on Tuesday.

The hold impacts the Phase I dose-escalation study ZN-c3-001 in solid tumours, the Phase II DENALI trial in platinum-resistant ovarian cancer (PROC), and the Phase II TETON study in uterine serous carcinoma. The sepsis cases occurred in the DENALI study.

“Patient safety is our top priority and any deaths that occur in the setting of clinical trials are unfortunate,” stated CEO Kimberly Blackwell, adding, “we are working closely with the FDA to resolve this partial clinical hold as quickly as possible.”

Despite the setback, Blackwell remains confident about azenosertib's therapeutic index, noting that over 500 patients have received the WEE1 inhibitor WEE1 inhibitor as monotherapy across various studies. DENALI's Cohort Ib alone enrolled over 100 PROC patients. "We look forward to sharing these results along with overall efficacy and safety data from DENALI Cohort Ib later this year," Blackwell added.

Phase Ib data reported last year showed a confirmed overall response of 50% and median progression-free survival of 7.4 months when azenosertib was combined with paclitaxel in PROC patients. Azenosertib is a potentially first-in-class WEE1 inhibitor WEE1 inhibitor targeting tumours with genomic instability, like PROC and uterine serous carcinoma. By blocking WEE1, Zentalis says its drug causes cancer cells to accumulate DNA damage, resulting in replication stress and apoptosis.

While resolving the clinical hold, Zentalis said it also plans to report Phase I/II data from the MAMMOTH study later this year evaluating azenosertib plus GSK's PARP-blocking drug Zejula (niraparib) in PROC patients. "Zentalis remains committed to… bringing this potentially practice-changing therapy to patients with gynaecological malignancies," the company stated.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构